Our Research

Discover our recent findings, catch up with news, and review in-depth resources and case studies.

Connect with Resolian at these upcoming events.

Navigating the Transition from Titanium Dioxide (TiO2) in Pharmaceuticals

Titanium dioxide (TiO2) has been a critical excipient in pharmaceuticals for decades, offering exceptional opacity, whiteness, and stability. However, evolving regulatory demands are driving the industry to explore alternatives. Resolian provides advanced analytical and characterization support to guide this transition while ensuring product quality and compliance.
Read more

Flow Cytometry Sample Processing Packages

Our Flow Cytometry team have designed a sample processing package that solves the logisitcally challenges with samples.
Read more
Harmonizing Quality Standards Across Global Labs

Harmonizing Quality Standards Across Global Labs with David Butler

In a globalized life sciences industry, maintaining consistent quality standards across multiple international sites is a major challenge.
Read more

Globally Harmonized Labs

Leading the Way in Secure, Cross-Border Analytical Solutions. We’re committed to delivering seamless scientific expertise that’s globally integrated and locally specialized. 
Read more

Biomarker Assay List

Our extensive biomarker method experience is outlined in the following list, but it’s not exhaustive.
Read more

Bioanalytical LC-MS/MS Assay List 

With 20+ years of working to GLP and GCP, we have developed an extensive number of LC-MS/MS bioanalytical methods in a wide range of species and matrices.
Read more
Scroll to Top

Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma

November 1, 2023

Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali Medpharma, a leading China-based bioanalytical CRO. Resolian now has bioanalysis laboratory operations in the U.S., U.K., Australia, and China. The company can initiate a project on four continents and easily transfer validated methods across labs, allowing therapeutic trials to extend to virtually any destination without changing bioanalytical CROs.

“The strategic addition of Denali will significantly enhance our capabilities and strengthen our position in the global market,” said Resolian CEO Patrick Bennett. “Denali’s founders and core scientists are internationally recognized across pharmaceutical research and development analysis and we are particularly excited to add Denali’s oligo, mRNA, and liposomal expertise to Resolian’s portfolio of services. We look forward to leveraging our growing company’s strengths to continue driving innovation and creating lasting value for our clients and stakeholders.”

 “The Denali team is thrilled to join Resolian,” said Denali CEO Min Meng, Ph.D. “Denali was founded by a group of U.S.-trained bioanalytical experts in a state-of-the-art lab facility in China to provide exceptional service for domestic and international clients. We look forward to continuing this track record and offering even greater capabilities and trial flexibility as part of Resolian.”

 

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.